WILSON TROY EDWARD 4

What Happened

• Troy E. Wilson, a director of Atrium Therapeutics, was granted a derivative award of 20,000 shares (reported as $0.00 cash price) on February 27, 2026. This filing (Form 4, accession 0001193125-26-085920) records an award/acquisition of derivative securities rather than an open-market purchase or sale.

Key Details

• Transaction date: February 27, 2026; Filing date: March 2, 2026 (timely).
• Transaction type/code: A — Grant/award (derivative security).
• Amount: 20,000 shares (derivative); reported price: $0.00 (no cash paid at grant).
• Vesting: Shares underlying the options vest in equal monthly installments over the three years following the grant, subject to continuous service (footnote F1).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No 10b5-1, tax-withholding, or late-filing flags noted in the provided data.

Context

• This was a compensation-style award of derivative securities (options/awards) to a director — a routine form of equity-based pay rather than a buy or sell that signals immediate market sentiment. The options vest gradually over three years; they may be exercised later (subject to plan terms) and are not the same as an immediate purchase of stock.